Journal article · 2026 · Open access
Normalized membrane ratio of TROP2 as a predictor of clinical outcomes with datopotamab deruxtecan in non-small-cell lung cancer
Nature Medicine · Published 11 November 2026 · DOI 10.1038/s41591-026-04716-9
In brief
“Normalized membrane ratio of TROP2 as a predictor of clinical outcomes with datopotamab deruxtecan in non-small-cell lung cancer” is a 2026 journal article by Marina Chiara Garassino and 24 co-authors, published in Nature Medicine. OpenAlex counts 0 citations as of 18 November 2026. It is open access under a CC BY licence: the full text is free to read at Nature Medicine.
- Citations
- 0
- References
- 67
- Authors
- 25
Abstract
Datopotamab deruxtecan (Dato-DXd)-a trophoblast cell surface antigen 2 (TROP2)-directed antibody-drug conjugate-has demonstrated efficacy in patients with advanced nonsquamous non-small-cell lung cancer (NSCLC) ± actionable genomic alterations. However, TROP2 expression by pathologist assessment using conventional immunohistochemistry with visual scoring does not predict response to TROP2-directed antibody-drug conjugates in NSCLC. We developed TROP2 quantitative continuous scoring (QCS)-a fully supervised computational pathology approach that quantifies TROP2 expression in individual NSCLC cells and subcellular components from immunohistochemistry-stained slides. Using QCS to determine TROP2 expression at the tumor cell membrane and cytoplasm, normalized membrane ratio (NMR) was developed (ratio of membrane relative to membrane + cytoplasmic TROP2) in the biomarker-evaluable population of patients with advanced NSCLC in the TROPION-PanTumor01 study (n = 115). The TROP2 NMR cut-point was optimized and validated in patients with nonsquamous NSCLC without actionable genomic alterations (primary intended-use population, n = 221) in the biomarker-evaluable population (n = 352) of the TROPION-Lung01 trial. Association with clinical outcomes was assessed. Progression-free survival was longer in Dato-DXd-treated (median 7.2 versus 4.0 months; hazard ratio 0.40, 95% confidence interval 0.25-0.64) but not docetaxel-treated (median 4.1 versus 4.4 months; hazard ratio 0.94, 95% confidence interval 0.59-1.49) patients with TROP2 NMR-positive versus TROP2 NMR-negative samples (treatment by biomarker status interaction P = 0.0098), indicating that TROP2 NMR may be a predictive biomarker for Dato-DXd.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Garassino, M. C., Ahn, M., Schick, M., Kapil, A., Paz-Ares, L. G., Lisberg, A. E., Johnson, M. L., Pérol, M., Shimizu, T., Heist, R. S., Spira, A. I., Okamoto, I., Girard, N., Cornelissen, R., Tostivint, E. P., Hong, M. H., Zwirtes, R. F., Chiaverelli, R. A., Rebelatto, M. C., . . . Sands, J. M. (2026). Normalized membrane ratio of TROP2 as a predictor of clinical outcomes with datopotamab deruxtecan in non-small-cell lung cancer. Nature Medicine. https://doi.org/10.1038/s41591-026-04716-9
MLA 9
Garassino, Marina Chiara, et al. “Normalized membrane ratio of TROP2 as a predictor of clinical outcomes with datopotamab deruxtecan in non-small-cell lung cancer.” Nature Medicine, 2026. https://doi.org/10.1038/s41591-026-04716-9.
Chicago
Garassino, Marina Chiara, Myung‐Ju Ahn, Markus Schick, Ansh Kapil, Luis G Paz-Ares, Aaron Elliott Lisberg, Melissa Lynne Johnson, et al. 2026. “Normalized membrane ratio of TROP2 as a predictor of clinical outcomes with datopotamab deruxtecan in non-small-cell lung cancer.” Nature Medicine. https://doi.org/10.1038/s41591-026-04716-9.
Harvard
Garassino, M. C. et al. (2026) ‘Normalized membrane ratio of TROP2 as a predictor of clinical outcomes with datopotamab deruxtecan in non-small-cell lung cancer’, Nature Medicine. doi:10.1038/s41591-026-04716-9.
IEEE
M. C. Garassino et al., “Normalized membrane ratio of TROP2 as a predictor of clinical outcomes with datopotamab deruxtecan in non-small-cell lung cancer,” Nature Medicine, 2026, doi: 10.1038/s41591-026-04716-9.
BibTeX
@article{garassino2026normalized,
title = {{Normalized membrane ratio of TROP2 as a predictor of clinical outcomes with datopotamab deruxtecan in non-small-cell lung cancer}},
author = {Garassino, Marina Chiara and Ahn, Myung‐Ju and Schick, Markus and Kapil, Ansh and Paz-Ares, Luis G and Lisberg, Aaron Elliott and Johnson, Melissa Lynne and Pérol, Maurice and Shimizu, Toshio and Heist, Rebecca Suk and Spira, Alexander I. and Okamoto, Isamu and Girard, Nicolas and Cornelissen, Robin and Tostivint, Elvire Pons and Hong, Min Hee and Zwirtes, Ricardo F. and Chiaverelli, Rachel A. and Rebelatto, Marlon Cezar and Sung, Matthew S. and Deng, Chuyu and Harper, James A. and Carroll, Danielle K. and Sade, Hadassah and Sands, Jacob M.},
journal = {Nature Medicine},
year = {2026},
doi = {10.1038/s41591-026-04716-9},
url = {https://doi.org/10.1038/s41591-026-04716-9}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Topic and keywords
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- TROP2
- datopotamab deruxtecan
- non-small cell lung cancer
- predictive biomarkers
- computational pathology
- antibody-drug conjugates
- progression-free survival
- actionable genomic alterations
Work with this paper
Most-cited papers in Medicine
- Yaşlı Kadınlarda Üreme SağlığıDemet Kokanalı, Yaprak Engin Üstün · Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi · 2019 · 169,630 citations
- Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 CountriesHyuna Sung, Adalberto M. Filho, Mathieu Laversanne and 5 more · CA A Cancer Journal for Clinicians · 2021 · 119,885 citations
- “Mini-mental state”Marshal F. Folstein, Susan E. Folstein, Paul R. McHugh · Journal of Psychiatric Research · 1975 · 90,424 citations
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesFreddie Bray, Jacques Ferlay, Isabelle Soerjomataram and 3 more · CA A Cancer Journal for Clinicians · 2018 · 87,396 citations
- Hallmarks of Cancer: The Next GenerationDouglas Hanahan, Robert A. Weinberg · Cell · 2011 · 69,758 citations
Questions about this paper
How do I cite this paper in APA style?
Garassino, M. C., Ahn, M., Schick, M., Kapil, A., Paz-Ares, L. G., Lisberg, A. E., Johnson, M. L., Pérol, M., Shimizu, T., Heist, R. S., Spira, A. I., Okamoto, I., Girard, N., Cornelissen, R., Tostivint, E. P., Hong, M. H., Zwirtes, R. F., Chiaverelli, R. A., Rebelatto, M. C., . . . Sands, J. M. (2026). Normalized membrane ratio of TROP2 as a predictor of clinical outcomes with datopotamab deruxtecan in non-small-cell lung cancer. Nature Medicine. https://doi.org/10.1038/s41591-026-04716-9
How many times has this paper been cited?
0 times, according to OpenAlex on 18 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at Nature Medicine: sign in and open the PDF from this page.
Who wrote this paper?
Marina Chiara Garassino, Myung‐Ju Ahn, Markus Schick, Ansh Kapil, Luis G Paz-Ares, Aaron Elliott Lisberg, Melissa Lynne Johnson, Maurice Pérol, Toshio Shimizu, Rebecca Suk Heist, Alexander I. Spira, Isamu Okamoto and 13 more.
What is the DOI of this paper?
10.1038/s41591-026-04716-9, permanently at https://doi.org/10.1038/s41591-026-04716-9. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 18 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.